In line with this, targeting Bcl-2 and mTOR concurrently (e.g., with everolimus, temsirolimus) was shown to synergize against Bcl-2-antagonist-resistant B-cell lines and primary acute lymphoblastic leukemia cells by down-regulation of Mcl-1 [11]. Here, BCL2 is linked to acute lymphoblastic leukemia.